- Home
- OEC vs MNMD Comparison
OEC vs MNMD Comparison
Compare OEC & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OEC
- MNMD
- Stock Information
- Founded
- OEC 1862
- MNMD 2019
- Country
- OEC Luxembourg
- MNMD United States
- Employees
- OEC N/A
- MNMD N/A
- Industry
- OEC Major Chemicals
- MNMD Pharmaceuticals and Biotechnology
- Sector
- OEC Industrials
- MNMD Health Care
- Exchange
- OEC Nasdaq
- MNMD Nasdaq
- Market Cap
- OEC 577.8M
- MNMD 509.2M
- IPO Year
- OEC 2014
- MNMD N/A
- Fundamental
- Price
- OEC $10.79
- MNMD $10.19
- Analyst Decision
- OEC Hold
- MNMD Strong Buy
- Analyst Count
- OEC 3
- MNMD 7
- Target Price
- OEC $11.33
- MNMD $24.71
- AVG Volume (30 Days)
- OEC 666.0K
- MNMD 1.1M
- Earning Date
- OEC 08-06-2025
- MNMD 07-31-2025
- Dividend Yield
- OEC 0.77%
- MNMD N/A
- EPS Growth
- OEC N/A
- MNMD N/A
- EPS
- OEC 0.26
- MNMD N/A
- Revenue
- OEC $1,841,700,000.00
- MNMD N/A
- Revenue This Year
- OEC N/A
- MNMD N/A
- Revenue Next Year
- OEC $4.90
- MNMD N/A
- P/E Ratio
- OEC $38.65
- MNMD N/A
- Revenue Growth
- OEC N/A
- MNMD N/A
- 52 Week Low
- OEC $9.03
- MNMD $4.70
- 52 Week High
- OEC $19.48
- MNMD $10.49
- Technical
- Relative Strength Index (RSI)
- OEC 53.86
- MNMD 62.33
- Support Level
- OEC $10.09
- MNMD $9.11
- Resistance Level
- OEC $10.42
- MNMD $10.03
- Average True Range (ATR)
- OEC 0.53
- MNMD 0.51
- MACD
- OEC 0.07
- MNMD -0.06
- Stochastic Oscillator
- OEC 80.69
- MNMD 78.26
About OEC Orion S.A.
Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing and special applications. Geographically, it derives a majority of its revenue from Germany.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).